StockNews.com Initiates Coverage on Trinity Biotech (NASDAQ:TRIB)

StockNews.com initiated coverage on shares of Trinity Biotech (NASDAQ:TRIB) in a research note issued to investors on Monday morning. The brokerage issued a buy rating on the stock.

Trinity Biotech Stock Performance

Shares of NASDAQ:TRIB opened at $2.85 on Monday. The firm has a 50 day simple moving average of $2.47 and a 200 day simple moving average of $2.23. Trinity Biotech has a 52 week low of $1.49 and a 52 week high of $4.95. The company has a market cap of $21.68 million, a PE ratio of -1.02 and a beta of 1.31.

Trinity Biotech (NASDAQ:TRIB) last posted its quarterly earnings data on Thursday, May 23rd. The company reported ($0.37) EPS for the quarter. The company had revenue of $14.70 million for the quarter. On average, equities analysts predict that Trinity Biotech will post -2.17 earnings per share for the current year.

Trinity Biotech Company Profile

Trinity Biotech plc acquires, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas and Ireland. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases consisting of syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic testing for haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.